[go: up one dir, main page]

DE60030861D1 - Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen - Google Patents

Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen

Info

Publication number
DE60030861D1
DE60030861D1 DE60030861T DE60030861T DE60030861D1 DE 60030861 D1 DE60030861 D1 DE 60030861D1 DE 60030861 T DE60030861 T DE 60030861T DE 60030861 T DE60030861 T DE 60030861T DE 60030861 D1 DE60030861 D1 DE 60030861D1
Authority
DE
Germany
Prior art keywords
escitalopram
treatment
generalized anxiety
anxiety
generalized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030861T
Other languages
English (en)
Other versions
DE60030861T2 (de
Inventor
Connie Sanchez
Sandra Hogg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60030861(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE60030861D1 publication Critical patent/DE60030861D1/de
Application granted granted Critical
Publication of DE60030861T2 publication Critical patent/DE60030861T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60030861T 1999-07-08 2000-07-07 Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen Expired - Lifetime DE60030861T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
DK990991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders

Publications (2)

Publication Number Publication Date
DE60030861D1 true DE60030861D1 (de) 2006-11-02
DE60030861T2 DE60030861T2 (de) 2007-05-03

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030861T Expired - Lifetime DE60030861T2 (de) 1999-07-08 2000-07-07 Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen

Country Status (38)

Country Link
US (6) US7271194B2 (de)
EP (4) EP1440689A3 (de)
JP (1) JP4773011B2 (de)
KR (1) KR100604176B1 (de)
CN (1) CN1198610C (de)
AR (1) AR021155A1 (de)
AT (1) ATE339955T1 (de)
AU (6) AU782514B2 (de)
BG (4) BG110466A (de)
BR (1) BR0011578A (de)
CA (4) CA2687396A1 (de)
CL (3) CL2008003939A1 (de)
CO (1) CO5190674A1 (de)
CY (1) CY1105806T1 (de)
CZ (1) CZ200270A3 (de)
DE (1) DE60030861T2 (de)
DK (1) DK1200081T3 (de)
EA (1) EA006555B1 (de)
ES (1) ES2272298T3 (de)
HK (1) HK1048069B (de)
HR (1) HRP20010820A2 (de)
HU (1) HUP0201791A3 (de)
IL (5) IL146131A0 (de)
IS (1) IS6137A (de)
ME (2) ME00032B (de)
MX (1) MXPA01011626A (de)
MY (1) MY143278A (de)
NO (4) NO329021B1 (de)
PL (1) PL352030A1 (de)
PT (1) PT1200081E (de)
SI (1) SI1200081T1 (de)
SK (1) SK82002A3 (de)
TR (4) TR200402276T2 (de)
TW (1) TWI232101B (de)
UA (1) UA77645C2 (de)
WO (1) WO2001003694A1 (de)
YU (1) YU78701A (de)
ZA (1) ZA200108856B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
PT1301502E (pt) * 2000-07-21 2005-09-30 Lundbeck & Co As H Compostos e sua utilizacao como inibidores do transporte de glicina
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.
MEP2108A (xx) 2001-07-31 2010-02-10 Lundbeck & Co As H Kristalni sastav koji sadrži escitalopram
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
ES2298595T3 (es) * 2002-12-23 2008-05-16 H. Lundbeck A/S Hidrobromuro de escitalopram y un metodo para su preparacion.
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (de) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
EP1208838A3 (de) 1991-11-15 2003-07-09 Sepracor Inc. Reines S(+)Fluoxetin Isomer
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
DE69607904T2 (de) 1995-08-16 2000-10-05 Eli Lilly And Co., Indianapolis Potenzierung von Serotonin-Wirkstoffresponz
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
CN1286687A (zh) * 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
US6353008B1 (en) * 1998-06-30 2002-03-05 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SK285719B6 (sk) * 1998-10-20 2007-07-06 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukty
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
JP3798940B2 (ja) * 1999-04-14 2006-07-19 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU5565401A (en) * 2000-04-24 2001-11-07 Aryx Therapeutics Materials and methods for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
MXPA03008777A (es) * 2001-05-01 2004-02-12 Lundbeck & Co As H El uso de escitalopram enantiomericamente puro.

Also Published As

Publication number Publication date
CA2687392A1 (en) 2001-01-18
EP1200081B1 (de) 2006-09-20
PL352030A1 (en) 2003-07-28
HRP20010820A2 (en) 2003-08-31
EP1440689A2 (de) 2004-07-28
TR200402277T2 (tr) 2005-01-24
AU2005202685B2 (en) 2009-01-15
JP2003504332A (ja) 2003-02-04
CA2687396A1 (en) 2001-01-18
AR021155A1 (es) 2002-06-12
EP1200081A1 (de) 2002-05-02
AU782514B2 (en) 2005-08-04
NO329021B1 (no) 2010-07-26
BR0011578A (pt) 2002-03-26
DE60030861T2 (de) 2007-05-03
AU2005202685A1 (en) 2005-07-14
TWI232101B (en) 2005-05-11
JP4773011B2 (ja) 2011-09-14
MY143278A (en) 2011-04-15
BG110467A (en) 2010-01-29
IL170194A (en) 2010-05-31
AU2005202684B2 (en) 2009-01-15
US20050101665A1 (en) 2005-05-12
EP1440689A3 (de) 2004-08-25
AU2005202686A1 (en) 2005-07-14
YU78701A (sh) 2004-03-12
EA200200137A1 (ru) 2002-06-27
PT1200081E (pt) 2007-01-31
BG110468A (en) 2010-01-29
CN1360501A (zh) 2002-07-24
HUP0201791A2 (en) 2002-10-28
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (de) 2004-07-28
AU2008264188A1 (en) 2009-05-07
ATE339955T1 (de) 2006-10-15
US7265151B2 (en) 2007-09-04
MEP2508A (xx) 2010-02-10
EP1440691A3 (de) 2004-08-25
AU2008264182A1 (en) 2009-01-29
NO20100333L (no) 2002-01-07
US6960613B2 (en) 2005-11-01
NO20100335L (no) 2002-01-07
AU2005202686B2 (en) 2009-01-15
HUP0201791A3 (en) 2005-02-28
EP1440690A2 (de) 2004-07-28
IL146131A0 (en) 2002-07-25
CL2008003938A1 (es) 2009-05-22
AU5806100A (en) 2001-01-30
IS6137A (is) 2001-10-30
HK1048069B (zh) 2005-12-16
KR100604176B1 (ko) 2006-07-25
ZA200108856B (en) 2002-12-24
TR200402275T2 (tr) 2005-03-21
EP1440690A3 (de) 2004-08-18
ME00032B (me) 2010-02-10
HK1048069A1 (en) 2003-03-21
DK1200081T3 (da) 2006-12-27
WO2001003694A1 (en) 2001-01-18
US20040029956A1 (en) 2004-02-12
US20040029957A1 (en) 2004-02-12
BG110466A (en) 2010-01-29
NO20020062D0 (no) 2002-01-07
CA2373757A1 (en) 2001-01-18
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
IL146131A (en) 2007-02-11
US20070276035A1 (en) 2007-11-29
CL2008003941A1 (es) 2009-05-22
CN1198610C (zh) 2005-04-27
EA006555B1 (ru) 2006-02-24
SK82002A3 (en) 2002-07-02
IL170192A (en) 2010-04-29
CZ200270A3 (cs) 2002-04-17
NO20100334L (no) 2002-01-07
US20040029958A1 (en) 2004-02-12
CO5190674A1 (es) 2002-08-29
UA77645C2 (en) 2007-01-15
CA2373757C (en) 2010-01-05
IL170193A (en) 2010-04-29
CL2008003939A1 (es) 2009-06-05
TR200402276T2 (tr) 2005-01-24
MXPA01011626A (es) 2002-06-04
TR200200014T2 (tr) 2002-05-21
BG106279A (bg) 2002-08-30
KR20020015346A (ko) 2002-02-27
CA2687394A1 (en) 2001-01-18
US20020086899A1 (en) 2002-07-04
US7271194B2 (en) 2007-09-18
CY1105806T1 (el) 2011-02-02
ES2272298T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
ATE394103T1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE50014041D1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Legal Events

Date Code Title Description
8363 Opposition against the patent